Taylor & Francis

People living with cancer have a profound need to understand any potential negative impacts of treatment on their everyday lives and whether the treatment itself could cause other long-term health challenges. This podcast brings together the perspectives of a patient, patient advocates and an oncologist, to highlight opportunities to better support people in understanding the possible side effects of a treatment and potential impact on quality of life. In addition to bridging gaps between the perspectives of healthcare providers and patients, it may be helpful to support people in interpreting relevant clinical trial findings. With this in mind, two accompanying visual guides use patient-friendly language to help people understand how safety and quality of life are measured in clinical trials.

https://doi.org/10.1080/14796694.2024.2422808

Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer by Taylor & Francis Group

Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer by Taylor & Francis Group

In this podcast discussion, we review the landscape of androgen deprivation therapies (ADT) for the treatment of advanced prostate cancer. Prior to 2020, available ADT options to achieve chemical castration included gonadotropin-releasing hormone receptor agonists (e.g., leuprolide) and antagonists (e.g., degarelix) administered via muscular or subcutaneous injection. In 2020, the once-daily oral gonadotropin-releasing hormone antagonist, relugolix, received US regulatory approval for the treatment of advanced prostate cancer based on results from the Phase III HERO trial. In this podcast, we also discuss the primary efficacy and safety results of this trial, and key points for providers and patients to consider as they discuss the different ADT options.

https://doi.org/10.1080/14796694.2024.2418801

Drs. Ramalingam and Carlisle discuss the incidence and pathophysiology of BRAF V600E-mutant metastatic non-small cell lung cancer and current treatment options. The podcast provides an overview of the data from the recent Pfizer-sponsored phase 2 PHAROS (NCT03915951) study, which were the basis for the recent US Food and Drug Administration approval of encorafenib plus binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer.

doi.org/10.1080/14796694.2024.2391270

Patients with advanced breast cancer in which the cancer cells have the receptor for the hormone estrogen and/or progesterone are typically treated with an aromatase inhibitor, a hormone therapy that decreases estrogen being made in the body, together with an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), a drug that blocks the growth of cancer cells. Although cancers usually respond to treatment initially, the cancer cells eventually change, so the drug combination no longer works. For example, mutation of the estrogen receptor (referred to as ESR1m) can stop aromatase inhibitors from working. Camizestrant is an investigational drug that blocks estrogen receptors, including mutated receptors, reducing the growth and spread of cancer. Here we describe the SERENA-6 clinical trial, which is testing camizestrant as a treatment for patients with breast cancer with ESR1m. How will we perform this research? The phase III SERENA-6 trial will use blood tests to monitor if patients with breast cancer develop ESR1m while being treated with an aromatase inhibitor and a CDK4/6 inhibitor. If ESR1m is detected, yet the disease is stable, participants will be randomly assigned to either continue with the same aromatase inhibitor or switch to camizestrant while continuing with the same CDK4/6 inhibitor. The study will assess whether switching to camizestrant prolongs the time before the cancer grows, spreads or worsens. It will also assess the length of time that participants live for versus those who continue with an aromatase inhibitor.

The patient authors with over 48 years of combined real-world experience with chronic myeloid leukemia, and a healthcare professional, use their own personal experiences to describe the factors that may affect the patiet–doctor relationship, patient care and outcomes. The authors believe that this podcast series and associated manuscript will aid both patients and healthcare professionals to improve their patient–doctor relationships and communication through diagnosis, treatment decision-making and learning to live with CML (or another disease). In this episode, they discuss managing financial costs and where to find resources and support groups.

This is podcast three in a series of three. - doi.org/10.2217/fon-2023-0404

Podcast 2 - The Journey: Staying on top of your Cancer - doi.org/10.2217/fon-2023-0403

The Beginning: Diagnosis and Selecting Your Doctor - doi.org/10.2217/fon-2023-0402

This podcast is related to this article - www.tandfonline.com/doi/full/10.2217/fon-2022-1267

The patient authors with over 48 years of combined real-world experience with chronic myeloid leukemia, and a healthcare professional, use their own personal experiences to describe the factors that may affect the patient–doctor relationship, patient care and outcomes. The authors believe that this podcast series and associated manuscript will aid both patients and healthcare professionals to improve their patient–doctor relationships and communication through diagnosis, treatment decision-making and learning to live with CML (or another disease). In this episode, they discuss the importance of the patient–doctor relationship, the patient authors' own diagnosis experiences and considerations when selecting a health care team.

This is podcast two in a series of three. - doi.org/10.2217/fon-2023-0403

The Beginning: Diagnosis and Selecting Your Doctor - doi.org/10.2217/fon-2023-0402

Podcast 3. Lessons Learned: Managing Financial Costs and where you can go for more Information - doi.org/10.2217/fon-2023-0404

This podcast is related to this article - www.tandfonline.com/doi/full/10.2217/fon-2022-1267

The patient authors with over 48 years of combined real-world experience with chronic myeloid leukemia, and a healthcare professional, use their own personal experiences to describe the factors that may affect the patient–doctor relationship, patient care and outcomes. The authors believe that this podcast series and associated manuscript will aid both patients and healthcare professionals to improve their patient–doctor relationships and communication through diagnosis, treatment decision-making and learning to live with CML (or another disease). In this episode, they discuss the importance of the patient–doctor relationship, the patient authors' own diagnosis experiences and considerations when selecting a health care team.

This is podcast one in a series of three. - https://doi.org/10.2217/fon-2023-0402

Podcast 2 - The Journey: Staying on top of your Cancer - https://doi.org/10.2217/fon-2023-0403

Podcast 3. Lessons Learned: Managing Financial Costs and where you can go for more Information - https://doi.org/10.2217/fon-2023-0404

This podcast is related to this article - https://www.tandfonline.com/doi/full/10.2217/fon-2022-1267

Christopher Lieu, co-director of gastrointestinal medical oncology and the associate director for clinical research at the University of Colorado Cancer Center (CO, USA) discusses the importance of biomarker testing in metastatic colorectal cancer to inform personalized patient care.

Find the article on Taylor & Francis - www.doi.org/10.2217/fon-2022-1293